Oric Pharmaceuticals/$ORIC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
- Ticker
- $ORIC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 111
- Headquarters
- South San Francisco, United States
- Website
- www.oricpharma.com
ORIC Metrics
BasicAdvanced
$958M
-
-$1.35
0.99
-
Price and volume
Market cap
$958M
Beta
0.99
52-week high
$14.68
52-week low
$7.23
Average daily volume
1.8M
Financial strength
Current ratio
13.186
Quick ratio
12.756
Long term debt to equity
0.007
Total debt to equity
0.007
Profitability
EBITDA (TTM)
-154.995
Management effectiveness
Return on assets (TTM)
-25.97%
Return on equity (TTM)
-39.80%
Valuation
Price to book
2.51
Price to tangible book (TTM)
2.51
Price to free cash flow (TTM)
-8.549
Free cash flow yield (TTM)
-11.70%
Free cash flow per share (TTM)
-1.081
Growth
Earnings per share change (TTM)
-28.52%
3-year earnings per share growth (CAGR)
-14.64%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Analyst projections of the future price of Oric Pharmaceuticals stock.
Bulls say / Bears say
In a 26-patient Phase 1b study, enozertinib produced an 84% confirmed systemic response rate and a 70% confirmed brain-tumour response rate, with no treatment-related discontinuations. ORIC plans to start a global Phase 3 trial in 2027. (ORIC Pharmaceuticals)
Rinzimetostat has advanced into Phase 3 for prostate cancer after early combination data showed an 84% five-month landmark rate for remaining free of radiographic progression. This gives ORIC a second late-stage programme, although the early results need confirmation in the larger trial. (ORIC Pharmaceuticals, ORIC Pharmaceuticals)
The company reported $388 million in cash and investments at the end of June 2026 and expects this to fund its current plan into the second half of 2028. That should help it advance both lead programmes without an immediate financing need. (ORIC Pharmaceuticals)
A rival prostate-cancer drug from Johnson & Johnson posted a 75% response rate among 16 patients with measurable disease in an early study. If its results hold up as development progresses, it could compete with rinzimetostat and weigh on ORIC’s opportunity. (Yahoo Finance)
Enozertinib’s encouraging results come from only 26 patients, and median progression-free survival and response duration are still immature. Its planned Phase 3 trial must show that the early response rates translate into lasting benefit. (ORIC Pharmaceuticals)
ORIC has no product revenue and continues to use substantial cash to fund research and trials; it reported a $77 million net loss for the first half of 2026. The company says it may need more capital, and further share sales could dilute existing investors. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Upcoming events
No upcoming events
ORIC News
AllArticlesVideos
Funds containing ORIC
Fund name | Fund size | $ORIC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.